Outcomes of Takotsubo cardiomyopathy in hospitalized cancer patients
- PMID: 29761372
- PMCID: PMC11813307
- DOI: 10.1007/s00432-018-2661-1
Outcomes of Takotsubo cardiomyopathy in hospitalized cancer patients
Abstract
Background: Chemotherapy-induced cardiomyopathy is a critical complication of treatment for cancer. The emotional stress of a cancer diagnosis, ongoing chemotherapy, abnormal cancer-related wasting syndrome may contribute to cardiac morbidity in these patients. The burden of Takotsubo Cardiomyopathy (TCM) in cancer patients is unknown. The incidence of TCM and related outcomes in cancer patients was investigated in this study.
Methods: The 2007-2013 National Inpatient Sample (NIS) was analyzed for patients with a prior and new diagnosis of TCM with and without malignancy. Risk factors for mortality were adjusted for associated conditions by multivariable logistic regression analysis.
Results: From 2007 to 2013, an estimated 122,855 adults were admitted with a diagnosis of TCM. In 2013, the incidence of admissions in US of patients with coexisting TCM and malignancy was 1.13%. Patients admitted for TCM with coexisting malignancy had a significantly higher mortality (13.8 vs. 2.9%, p < 0.0001), length of stay (7 vs. 4 days, p < 0.0001) and total charges ($29,291 vs. $36,231, p < 0.0001), compared to those with no malignancy. In patients with a primary diagnosis of TCM and without any underlying malignancy, males had a higher mortality (4.02 vs. 1.03%, p < 0.0001), whereas there was no gender difference in mortality in those with coexisting malignancy (6.25 vs. 6.45%, p = 0.965). On multivariable logistic regression analysis, risk factors associated with mortality were solid cancer (OR 3.43, p = 0.008), stroke (OR 18.33, p < 0.0001) and heart failure (OR 1.918, p = 0.004).
Conclusions: Outcomes are significantly worse in patients with TCM and malignancy. Hence, this patient population must be regarded as high-risk and early diagnostic consideration for TCM is warranted. Early intervention may help lower mortality, decrease resource utilization and reduce the health care costs in these patients.
Keywords: Cancer; Mortality; Outcomes; Stress cardiomyopathy.
Conflict of interest statement
The authors declare that they have no competing interest.
Figures
Similar articles
-
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100. Epidemiol Prev. 2013. PMID: 23851286 Italian.
-
Nutritional interventions for survivors of childhood cancer.Cochrane Database Syst Rev. 2016 Aug 22;2016(8):CD009678. doi: 10.1002/14651858.CD009678.pub2. Cochrane Database Syst Rev. 2016. PMID: 27545902 Free PMC article.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Prognostic Value of Frailty in Patients With Takotsubo Cardiomyopathy.Clin Cardiol. 2025 Jan;48(1):e70054. doi: 10.1002/clc.70054. Clin Cardiol. 2025. PMID: 39817430 Free PMC article.
-
Non-pharmacological interventions for preventing delirium in hospitalised non-ICU patients.Cochrane Database Syst Rev. 2021 Jul 19;7(7):CD013307. doi: 10.1002/14651858.CD013307.pub2. Cochrane Database Syst Rev. 2021. PMID: 34280303 Free PMC article.
Cited by
-
Prognostic factors of Takotsubo cardiomyopathy: a systematic review.ESC Heart Fail. 2021 Oct;8(5):3663-3689. doi: 10.1002/ehf2.13531. Epub 2021 Aug 9. ESC Heart Fail. 2021. PMID: 34374223 Free PMC article.
-
Takotsubo Syndrome: Translational Implications and Pathomechanisms.Int J Mol Sci. 2022 Feb 10;23(4):1951. doi: 10.3390/ijms23041951. Int J Mol Sci. 2022. PMID: 35216067 Free PMC article. Review.
-
Takotsubo Cardiomyopathy: Current Treatment.J Clin Med. 2021 Aug 2;10(15):3440. doi: 10.3390/jcm10153440. J Clin Med. 2021. PMID: 34362223 Free PMC article. Review.
-
Cardiogenic shock among cancer patients.Front Cardiovasc Med. 2022 Aug 22;9:932400. doi: 10.3389/fcvm.2022.932400. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36072868 Free PMC article. Review.
-
Association Between Mortality and Left Ventricular Ejection Fraction in Patients With Takotsubo Syndrome Versus Acute Coronary Syndrome.In Vivo. 2020 Nov-Dec;34(6):3639-3648. doi: 10.21873/invivo.12210. In Vivo. 2020. PMID: 33144479 Free PMC article.
References
-
- Baumann S, Huseynov A, Goranova D, Faust M, Behnes M, Nolte F et al (2014) Takotsubo cardiomyopathy after systemic consolidation therapy with high-dose intravenous cytarabine in a patient with acute myeloid leukemia. Oncol Res Treat 37(9):487–490. 10.1159/000365536 - PubMed
-
- Burgdorf C, Kurowski V, Bonnemeier H, Schunkert H, Radke PW (2008) Long-term prognosis of the transient left ventricular dysfunction syndrome (Tako-Tsubo cardiomyopathy): focus on malignancies. Eur J Heart Fail 10(10):1015–1019. 10.1016/j.ejheart.2008.07.008 - PubMed
-
- Burgdorf C, Nef HM, Haghi D, Kurowski V, Radke PW (2010) Tako-tsubo (stress-induced) cardiomyopathy and cancer. Ann Intern Med 152(12):830–831. 10.7326/0003-4819-152-12-201006150-00026 - PubMed
-
- Dote K, Sato H, Tateishi H, Uchida T, Ishihara M (1991) Myocardial stunning due to simultaneous multivessel coronary spasms: a review of 5 cases. J Cardiol 21(2):203–14 - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources